#South Korea #Seoul #Lunit #Cancer #Immune

Lunit's Breakthroughs at SITC 2025: Mapping Tumor-Immune Landscapes

At the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held from November 5-9, 2025, Lunit presented an impressive portfolio of research that advances the intersection of artificial intelligence (AI) and cancer treatment. The studies showcased how Lunit's AI platforms, including the Lunit SCOPE IO® and Lunit SCOPE uIHC, can effectively predict responses to immunotherapy and identify promising new antibody targets.

Standardizing Immunophenotyping with Lunit SCOPE IO

In a collaborative study with CellCarta, Lunit demonstrated the potential of Lunit SCOPE IO to standardize tumor immune phenotyping across various cancer types, such as non-small cell lung, colorectal, and urothelial cancers. Utilizing AI to assess tumor and stromal segmentation, the platform showed a remarkable correlation with pathologist assessments, achieving Spearman's correlation coefficients of 0.91 and 0.86.

This technological advancement not only improves the alignment between AI-based evaluations and traditional scoring methods but also enhances the reliability and reproducibility of immune profiling. By allowing for a consistent analysis of the tumor immune microenvironment, Lunit SCOPE IO reduces the dependency on additional immunohistochemical (IHC) staining, streamlining both research and clinical applications.

Accelerating Antibody-Based Therapeutics with Lunit SCOPE uIHC

In another exciting presentation, Lunit introduced new data illustrating the capabilities of Lunit SCOPE uIHC—an AI-powered quantitative IHC platform. This technology maps spatial interactions between tumor-infiltrating lymphocytes (TILs) and a wide range of membrane-specific protein targets. Analyzing over 47,000 IHC images across 34 cancer types, the study revealed intriguing correlations between immune cell density and protein expression levels. While many protein targets indicated decreased TIL density, notable exceptions like PD-L1 showed a positive relationship with lymphocyte infiltration. Furthermore, FGFR4 expression was linked to higher levels of intra-tumoral lymphocytes in specific cancers, suggesting FGFR4 as a potential target for bispecific T-cell engagers (BiTEs).

Predictive Power of Spatial Profiling

Another highlight of Lunit's presentations was a study confirming the predictive power of AI-based spatial profiling in MET-mutated non-small cell lung cancer (NSCLC). This work illustrates how AI-driven imaging can uncover unique immunologically active subtypes within tumors, furthering the understanding of cancer biology and treatment options.

Brandon Suh, CEO of Lunit, reflects on the significance of these findings: "At SITC 2025, we're showcasing how our digital pathology AI, the Lunit SCOPE suite, can bridge research and real-world clinical practice. From identifying immunotherapy-responsive subtypes to guiding antibody-based drug discovery, our AI technology is redefining how we understand and target the tumor–immune interface." He adds that the collaborations with companies like CellCarta are essential to bringing the full potential of these innovations to fruition.

Studies Presented at SITC 2025

Lunit's contributions to the SITC 2025 included significant research papers and presentations:

• - Poster Presentation [#1347]: AI-powered image-based spatial profiling of MET-mutated non-small cell lung cancer identifies immune-active MET exon 14 skipping subtypes as potential immunotherapy targets, presented by Zachary Wallen, Labcorp Oncology.
• - Poster Presentation [#1264]: Artificial Intelligence-Powered Spatial Analysis of Tumor Microenvironment Identifies Immune Phenotypes in HE Stained Non-Small Cell Lung Cancer, Colorectal Cancer, and Urothelial Cancer, presented by Elizabeth Ross, CellCarta.
• - Poster Presentation [#1098]: Unveiling spatial correlation between cell surface targets and lymphocytes via artificial intelligence (AI)-powered quantitative immunohistochemistry (IHC) analysis, presented by Sukjun Kim, Lunit.

To explore more about Lunit’s innovative solutions in AI-powered digital pathology and groundbreaking oncology research, attendees can visit Lunit at booth #818.

About Lunit

Founded in 2013, Lunit (KRX:328130) has positioned itself as a global leader in AI-powered cancer diagnostics, aiming to revolutionize cancer care. With clinically validated solutions spanning medical imaging and biomarker analysis, Lunit is dedicated to enhancing early detection, optimizing treatment strategies, and improving patient outcomes.

Following its integration with Volpara, Lunit has expanded its suite to incorporate risk prediction and precision oncology tools, with FDA-cleared platforms currently assisting cancer screening in numerous medical institutions worldwide. Trusted by over 10,000 facilities across 65 countries, Lunit combines deep medical knowledge with an ever-evolving data landscape to drive measurable impacts in the battles against cancer. Headquartered in Seoul, the company continues to empower healthcare professionals and researchers alike.

For more information, visit lunit.io/en.